January 9, 2026
From jab to snack-back
People who come off slimming jabs regain weight four times faster than dieters
Quit the shots, watch hunger roar back — commenters split on lifelong meds vs willpower
TLDR: New research says people who quit weight-loss shots regain weight around four times faster than dieters, likely due to rebound hunger. Comments are split: some call for lifelong treatment, others demand lifestyle changes and slam the hype, making this a big deal for millions now using these drugs.
The headline grabbed everyone — “slimming jabs” — and the comments immediately went feral. One user rolled their eyes at the word “jabs,” while others zeroed in on the real story: a BMJ study says people who stop weight-loss shots like Wegovy/Mounjaro regain weight about four times faster than folks who quit regular dieting. Translation: after quitting, the scale can creep up roughly 0.8 kg a month, with some saying it feels like a “hunger switch” flipping back on. Personal stories landed hard: one ex-Zepbound user admitted, “I was enjoying food again,” insisting the drug didn’t scam them — cravings just came roaring back.
Cue the brawl. The “lifelong meds” camp compares this to insulin: if it manages a chronic condition, why not stay on it? Others push back with the classic willpower vs. Big Pharma showdown. Lifestyle advocates argue shots are just tools, not miracles, and say learning to cook, shop better, and build habits matters. Anti-hype voices dunked on the marketing — remember the promise to “bankrupt fast food”? Now it’s looking more like a subscription plan for hunger management.
Meanwhile, memes flew: “Hunger speedrun,” “Snack-back multiplier,” and “GLP-1 or GLP-None?” The community isn’t just split — it’s sizzling with takes, from practical to cynical to downright hangry.
Key Points
- •BMJ meta-analysis finds people stopping Wegovy/Mounjaro regain weight about four times faster than those ending conventional dieting (≈0.8 kg/month vs ≈0.1 kg/month).
- •Users typically lose about 20% of body weight on injections but may return to pre-treatment weight in roughly 18 months after stopping.
- •The review analyzed 37 studies with >9,000 participants; only eight involved newer GLP-1 drugs, with up to one year of post-cessation follow-up, making some estimates provisional.
- •NHS recommends these drugs for overweight individuals with obesity-related risks and alongside lifestyle changes; many clinicians view treatment as potentially long-term due to relapse risk.
- •An expert explains GLP-1 drugs mimic a hunger-regulating hormone, and stopping may trigger appetite rebound, especially without established behavioral changes.